- Home
- MNSB vs HUMA Comparison
MNSB vs HUMA Comparison
Compare MNSB & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MNSB | HUMA |
|---|---|---|
| Founded | 2003 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.1M | 165.7M |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MNSB | HUMA |
|---|---|---|
| Price | $22.10 | $0.44 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $1.63 |
| AVG Volume (30 Days) | 32.5K | ★ 5.9M |
| Earning Date | 10-26-2026 | 11-10-2026 |
| Dividend Yield | ★ 1.85% | N/A |
| EPS Growth | ★ 210.00 | 79.37 |
| EPS | ★ 1.05 | N/A |
| Revenue | ★ $135,615,000.00 | $2,038,000.00 |
| Revenue This Year | N/A | $72.32 |
| Revenue Next Year | N/A | $518.79 |
| P/E Ratio | $20.91 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.97 | $0.34 |
| 52 Week High | $25.87 | $1.53 |
Technical Indicators
Market Signals| Indicator | MNSB | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 39.28 | 48.49 |
| Support Level | $21.32 | $0.34 |
| Resistance Level | $25.32 | $0.46 |
| Average True Range (ATR) | 0.80 | 0.05 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 28.59 | 43.92 |
Price Performance
Historical ComparisonAbout MNSB MainStreet Bancshares Inc.
MainStreet Bancshares Inc is a bank holding company. It is focused on serving the borrowing, cash management and depository needs of small to medium-sized businesses, and professional practices and retail customers. The bank's products and services include business and consumer checking, premium interest-bearing checking, business account analysis, savings, certificates of deposit and other depository services, as well as a broad array of commercial, real estate and consumer loans.
About HUMA Humacyte Inc.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.